Successful Phase III OAK trial for Tecentriq (atezolizumab) + docetaxel for metastatic NSCLC patients whose disease progressed after treatment with platinum-based chemotherapy.-Genentech + Roche

Genentech, announced positive results for Tecentriq from the Phase III study, OAK. The study met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has been previously observed for Tecentriq. Genentech looks forward to presenting full results at an upcoming medical meeting in 2016.

Comment: Genentech has eight Phase III lung studies underway evaluating Tecentriq alone or in combination with other treatments in people with early and advanced stages of lung cancer.The drug has Breakthrough Therapy Designation and a Priority Review at the FDA with an action date of 10 October 2016. The FDA has given accelerated approval to Tecentriq for the treatment of people with locally advanced or metastatic urothelial carcinoma .